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Abstract
Introduction Nuclear medicine parathyroid imaging is important in the identification of hyperfunctioning parathyroid glands in
primary hyperparathyroidism (pHPT), but it may be also valuable before surgical treatment in secondary hyperparathyroidism
(sHPT). Parathyroid radionuclide imaging with scintigraphy or positron emission tomography (PET) is a highly sensitive
procedure for the assessment of the presence and number of hyperfunctioning parathyroid glands, located either at typical sites
or ectopically. The treatment of pHPT ismostly directed towardminimally invasive parathyroidectomy, especially in cases with a
single adenoma. In experienced hands, successful surgery depends mainly on the exact preoperative localization of one or more
hyperfunctioning parathyroid adenomas. Failure to preoperatively identify the hyperfunctioning parathyroid gland challenges
minimally invasive parathyroidectomy and might require bilateral open neck exploration.
Methods Over a decade has now passed since the European Association of Nuclear Medicine (EANM) issued the first edition of
the guideline on parathyroid imaging, and a number of new insights and techniques have been developed since. The aim of the
present document is to provide state-of-the-art guidelines for nuclear medicine physicians performing parathyroid scintigraphy,
single-photon emission computed tomography/computed tomography (SPECT/CT), positron emission tomography/computed
tomography (PET/CT), and positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with pHPT, as
well as in those with sHPT.
Conclusion These guidelines are written and authorized by the EANM to promote optimal parathyroid imaging. They will assist
nuclear medicine physicians in the detection and correct localization of hyperfunctioning parathyroid lesions.
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Preamble
The European Association of Nuclear Medicine (EANM) is a
professional non-profit medical association that facilitates
communication worldwide among individuals pursuing clini-
cal and research excellence in nuclear medicine. The EANM
was founded in 1985.
These guidelines are intended to assist practitioners in pro-
viding appropriate nuclear medicine care for patients. They
are not inflexible rules or requirements of practice and are
not intended, nor should they be used, to establish a legal
standard of care.
The ultimate judgment regarding the propriety of any spe-
cific procedure or course of action must be made by medical
professionals taking into account the unique circumstances of
each case. Thus, there is no implication that an approach dif-
fering from the guidelines, standing alone, is below the stan-
dard of care. To the contrary, a conscientious practitioner may
responsibly adopt a course of action different from that set out
in the guidelines when, in the reasonable judgment of the
practitioner, such course of action is indicated by the condition
of the patient, limitations of available resources, or advances
in knowledge or technology subsequent to publication of the
guidelines. The practice of medicine involves not only the
science but also the art of dealing with the prevention, diag-
nosis, alleviation, and treatment of disease.
The variety and complexity of human conditions make it
impossible to always reach the most appropriate diagnosis or
to predict with certainty a particular response to treatment.
Therefore, it should be recognized that adherence to these
guidelines will not ensure an accurate diagnosis or a success-
ful outcome.
All that should be expected is that the practitioner will
follow a reasonable course of action based on current knowl-
edge, available resources, and the needs of the patient to de-
liver effective and safe medical care. The sole purpose of these
guidelines is to assist practitioners in achieving this objective.
Introduction
Primary hyperparathyroidism is an endocrine disorder caused
by one or more hyperfunctioning parathyroid glands. The sus-
picion of pHPT is typically raised by the detection of hyper-
calcemia and/or its associated symptoms. Parathyroid hor-
mone (PTH) serum concentration is elevated, or within nor-
mal limits but inappropriate considering the presence of hy-
percalcemia. A rare type of pHPT is normocalcemic hyper-
parathyroidism presenting with normal serum calcium levels
but an elevated PTH concentration [1].
Primary hyperparathyroidism is the third most common
endocrine disease [2], affecting women 2–3 times more often
than men [3]. It is caused by the hyperfunction of one or more
parathyroid glands, which are overproducing PTH.
Hyperfunctioning parathyroid glands are solitary adenomas
in the majority of cases. Approximately 15–20% of cases are
caused by multiglandular disease (MGD) [4], i.e., multiple
adenomas or hyperplasia, while parathyroid carcinoma ac-
counts for less than 1% of cases. The majority of pHPT cases
(95%) occur sporadically, but approximately 5% are part of
hereditary syndromes, such as multiple endocrine neoplasia
types 1, 2, and 4 (MEN-1, MEN-2, and MEN-4) and
hyperparathyroidism-jaw tumor syndrome, or as part of non-
syndromic familial pHPT [5].
Familial hypocalciuric hypercalcemia, a potential differen-
tial diagnosis to pHPT, has to be recognized as it usually does
not require surgery.
Secondary hyperparathyroidism is a disorder characterized
by increased serum PTH levels due to parathyroid gland hy-
perplasia, triggered by hypocalcemia, hyperphosphatemia, or
decreased serum vitamin D concentration. The most common
causes of sHPT are vitamin D deficiency and chronic renal
disease. Sometimes pHPT and vitamin D deficiency occur
simultaneously, which results in decreased or normal serum
calcium levels. Rarer causes are long-term treatment with lith-
ium or magnesium, intestinal malabsorption or malnutrition,
or sunitinib treatment.
The therapy of sHPT depends on the primary cause. In the
case of renal HPT, therapy mainly consists of a restriction of
dietary intake together with medical treatment with
calcimimetics, vitamin D analogues, and phosphorus binders
[6]. Still, parathyroidectomy is required in patients with renal
sHPT refractory to medical treatment, i.e., in approximately
15% of patients after 10 years and 38% of patients after
20 years of renal dialysis therapy [7].
Paraneoplastic hyperparathyroidism is rare. In most cases it
is due to parathyroid hormone-related peptide (PTH-rp) pro-
duction and the serum level of PTH is low in relation to hy-
percalcemia. In rare cases, the culprit cancer produces PTH or
both PTH and PTH-rp, while no hyperfunctioning parathyroid
gland is present [8]. Most commonly, the PTH-rp secreting
malignancies include squamous cell carcinoma (lung, head
and neck, cervix) and some other solid tumors.
Parathyroid glands are typically located along both thyroid
lobes. The superior parathyroid glands develop from the 4th
pharyngeal pouch and descend with the thyroid. They are
located dorsal to the middle and upper poles of the thyroid,
and above the inferior thyroid artery. The inferior parathyroid
glands develop from the 3rd pouch and descend with the thy-
mus to ultimately remain close to the lower thyroid pole, and
more laterally [9]. Superior and inferior parathyroid glands
have a different relationship to the recurrent laryngeal nerve,
with the superior ones lying posterior to it, and the inferior
ones anterior to it.
2802 Eur J Nucl Med Mol Imaging (2021) 48:2801–2822
The incidence of ectopic parathyroid glands is approxi-
mately 16% [10]. An ectopically located gland may be one
of the four standard parathyroid glands or a supernumerary
gland. Most individuals (84%) have four parathyroid glands,
two superior and two inferior glands, while supernumerary
glands exist in 3 to 13% of individuals [11]. The total number
of parathyroid glands in an individual with supernumerary
glands may vary from 5 to 8 in number [12]. Rarely, in less
than 3% of cases, individuals may have only 3 glands [11].
Acquired ectopy of upper parathyroid glands is frequently
encountered along the tracheoesophageal groove ormore rare-
ly retroesophageally. They are usually in a lower position than
expected (prolapsed glands) [13]. Moreover, ectopic glands
can be located anywhere along the migratory path [14], from
the carotid bifurcation to the pericardium. Ectopic sites, there-
fore, include but are not limited to, a high cervical position, the
carotid sheath, an intrathyroidal location, intrathymic location,
mediastinal location, or the paraesophageal region [15]. Very
rarely, they can also be located in the pericardium [16, 17].
However, the most common location for ectopic upper para-
thyroid glands is along the esophagus, while ectopic lower
parathyroid glands most often have an intrathymic location
[9].
Histologically, parathyroid glands consist of a chief,
oxyphil, transitional oxyphil, and water-clear cells. Chief cells
are the most abundant cells [18]. They have a secretory func-
tion and are responsible for synthesizing and secreting PTH.
Oxyphil cells are rich in mitochondria and their function is
still unclear [19]. The function of water-clear cells is not clear-
ly understood as well.
Owing to the abundance of mitochondria within the
oxyphil cells, there is a high accumulation of [99mTc]Tc-
MIBI and [99mTc]Tc-tetrofosmin in hyperfunctioning para-
thyroid glands.
Radionuclide parathyroid imaging reveals hyperfunction-
ing parathyroid glands located at typical sites as well as ectop-
ically. Using planar scintigraphy or SPECT, sensitivity is
greater for adenomas compared with hyperplasia.
Hyperplastic parathyroid glands are usually smaller than ade-
nomas, which is associated with decreased sensitivity of ra-
dionuclide imaging [20]. Other factors may also contribute to
reduced sensitivity for MGD (e.g., tracer washout from some
lesions in dual-phase imaging, the inhibitory effect of hyper-
calcemia, etc.). However, it is important to recognizeMGD, as
it holds implications for a successful surgery. Each subsequent
surgery in a postoperative neck is technically challenging and
carries an additional risk of complications, including failure to
remove the culprit gland(s).
For the reasons stated above, it is necessary to identify the
most sensitive and specific diagnostic procedure to detect hy-
perfunctioning parathyroid glands. The currently most wide-
spread preoperative imaging procedure is the combination of
[99mTc]Tc-MIBI scintigraphy and cervical ultrasonography
(cUS), yielding a sensitivity of 81–95% [21, 22], which is
mainly contributed by [99mTc]Tc-MIBI scintigraphy.
Cervical ultrasonography can be combined with targeted
fine-needle aspiration (FNA) cytology and detection of PTH
in the aspirate (FNA-PTH) in order to increase specificity and
confirm the diagnosis of hyperfunctioning parathyroid lesions
in sonographically accessible locations [23]. Fine-needle as-
piration cytology is recommended in highly selected cases,
e.g., atypical cUS presentation and uninformative
[99mTc]Tc-MIBI. In case of negative standard imaging,
second-l ine imaging may be performed, such as
N - [ ( 1 8 F ) f l u o r o m e t h y l ] - 2 - h y d r o x y - N , N -
dimethylethanaminium ([18F]FCH or [18F]fluorocholine)
PET/CT, L-[methyl-11C]methionine ([11C]MET) PET/CT,
[11C]2-hydroxy-N,N,N-trimethylethanamium ([11C]CH)
PET/CT, so-called four-dimensional computed tomography
(4D-CT), MRI, [18F]fluorocholine PET/4D-CT or
[18F]fluorocholine PET/MRI. [18F]fluorocholine PET/CT is
also considered a potential “alternative” first-line method
whenever possible, as it appears to be an effective technique
even in patients with negative or equivocal standard imaging
findings. It is particularly useful in patients with sHPT
[24–26]. Before revision surgery and/or in the case of negative
imaging techniques, invasive techniques, such as selective
venous sampling or selective arteriography, may be
performed.
Goals
The EANM practice guidelines for parathyroid imaging are
written for nuclear medicine practitioners to promote the use
of optimal parathyroid imaging based on current knowledge.
The purpose of these recommendations is to assist in the per-
formance, the correct interpretation, and reporting of the re-
sults of the parathyroid imaging.
Background
Primary hyperparathyroidism is defined as high serum PTH
levels due to the presence of enlarged hyperfunctioning para-
thyroid gland(s). It is the most common cause of elevated
calcium levels in the ambulatory setting [3], although
calcemia in some cases may be normal. Rarely, PTH levels
are normal with concomitant hypercalcemia. Primary hyper-
parathyroidism represents a considerable public health prob-
lem due to its high incidence and repercussions to patients’
health. Therapy primarily consists of the surgical removal of
the hyperfunctioning parathyroid gland(s) [27]. Symptomatic
patients require treatment and generally undergo parathyroid-
ectomy, which is the only definitive therapy. Surgery is also
an important option in asymptomatic patients who can
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develop hypercalcemia and target organ involvement later in
life [28]. If surgery is indicated, preoperative localization of
the hyperfunctioning gland(s) allows for selective parathy-
roidectomy, reducing operation time, complications and hos-
pitalization, improving postoperative recovery, and resulting
in a better cosmetic outcome, and greater patient satisfaction
[29, 30]. Nuclear medicine techniques and cUS are crucial in
identifying and localizing hyperfunctioning parathyroid
glands. Both methods have advantages, as well as limitations.
The advantage of radionuclide parathyroid imaging over cUS
lies in the identification of ectopic glands [31], as well as in
easier recognition of posteriorly located upper glands [32].
Arguably it also enables an easier recognition of typically
located hyperfunctioning parathyroid glands in the back-
ground of thyroiditis. It is known that thyroiditis is usually
followed by enlarged lymph nodes that are sometimes imitat-
ing hyperfunctioning parathyroid glands on cUS [33]. On the
other hand, suspected hyperfunctioning parathyroid glands in
the neck on radionuclide imaging can be further examined
with cUS in order to avoid false-positive results. In patients
with multinodular goiter, [99mTc]Tc-MIBI scintigraphy might
be false negative, and cUS is mandatory [34]. In these cases,
dual-tracer methods and [18F]fluorocholine PET/CT are use-
ful as well [35]. Additionally, cUS is a valuable method for
excluding coexisting thyroid pathology in most cases, al-
though in toxic multinodular goiter or thyroid remnants after
hemithyroidectomy dual-tracer methods are helpful as well. If
a hyperfunctioning parathyroid gland is identified during cUS,
radionuclide imaging may still prove to be useful because of
possible undetected MGD, as well as ectopic glands. For the
reasons stated above, in addition to radionuclide parathyroid
gland imaging, using SPECT and/or PET tracers, these guide-
lines will also discuss ultrasound of the parathyroid glands as
the main complementary diagnostic imaging modality.
Additionally, the use of 4D CT, MRI, and invasive techniques
in identifying abnormal parathyroid glands will be addressed
in brief.
Indications
Radionuclide parathyroid imaging is used for the localization
of one or more hyperfunctioning parathyroid glands in pa-
tients with pHPT, and not for the diagnosis of hyperparathy-
roidism (HPT). It might be also valuable before surgical treat-
ment in sHPT due to possible detection of ectopic and super-
numerary glands, as well as a parathyroid gland with the low-
est [99mTc]Tc-MIBI uptake which may be partially
autografted or preserved [36, 37]. Périé et al. recommend a
combination of cUS and dual-tracer scintigraphy for routine
use to localize hyperfunctioning parathyroid glands in patients
with renal HPT undergoing surgical treatment [38]. However,
surgeons usually do not order [99mTc]Tc-MIBI scintigraphy
before primary surgery for renal hyperparathyroidism, and
bilateral open neck exploration is considered in these patients.
Still, radionuclide imaging may be helpful in cases of revision
surgery. In such circumstances, a combination of imaging
modalities is often required [37].
Radionuclide imaging is useful preoperatively to guide the
surgeon toward the exact location of one or more hyperfunc-
tioning parathyroid glands, especially in the case of ectopic
glands that cannot be visualized with cUS. Correct preopera-
tive localization may shorten the duration of surgery, which
nowadays mostly consists of minimally invasive parathyroid-
ectomy combined with intraoperative PTH determination,
particularly in single-gland disease. In the past, bilateral open
neck exploration was the standard surgical approach.
However, both techniques are appropriate and accomplish
high cure rates [39]. Excision of all hyperfunctioning parathy-
roid glands is pivotal for successful parathyroidectomy.
Radionuclide parathyroid imaging is especially useful in
patients with recurrent disease because the second operation
is technically more challenging than the first one, and hence a
precise preoperative localization of hyperfunctioning parathy-
roid gland(s) is important.
Radionuclide parathyroid imaging is also useful in con-
junction with cUS, foremost in patients with hereditary disor-
ders, such as MEN-1, MEN-2, and MEN-4, although sensi-
tivity for hyperplasia is lower compared with sporadic adeno-
ma. In this context, PET/CT might be preferred, owing to its
higher spatial resolution [40]. The identification of hyperfunc-
tioning glands can be supported by a γ-probe during surgery,
especially in patients who underwent previous surgical treat-
ment [41].
Precautions
It is necessary to exclude pregnancy in women of childbearing
age.
In pregnant patients, radionuclide imaging should only be
performed if deemed absolutely necessary, as decided by a
multidisciplinary team. Otherwise, it should be postponed af-
ter pregnancy. Instead, cUS and MRI may be preferred in this
case.
For more information, we advise to consult the American
College of Radiology (ACR) Practice Guideline for imaging
pregnant or potentially pregnant adolescents and women with
ionizing radiation [42].
In breastfeeding women, it is recommended to consult the
International Commission on Radiological Protection (ICRP)
Publication 128: Radiation Dose to Patients from
Radiopharmaceuticals: A Compendium of Current
Information Related to Frequently Used Substances [43].
When using 99mTc-labeled radiopharmaceuticals, interruption
of breastfeeding is not essential if free pertechnetate is absent
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in the radiopharmaceutical. However, a pause of 24 h during
which expressed feeds are discarded is recommended in some
summaries of product characteristics (SmPC) of 99mTc labeled
radiopharmaceuticals with marketing authorization. In the
case of Na[99mTc]TcO4, which is used for subtraction imag-
ing, a 12 h pause is recommended. For Na[123I]I,
breastfeeding interruption for > 3 weeks is advised due to
the risk of other iodine isotope contamination. However, if
the product has high purity (> 99.65%), the pause may be
shorter. In the SmPC of some Na[123I]I preparations, 1–
3 days pause is recommended, and breastfeeding can be
restarted when the activity level in the milk has reduced so
that it will not result in a radiation dose to the child greater
than 1 mSv. To be on the safe side we recommend a 3-day
pause. It is not known whether [11C]CH, 18F-labeled choline
analogues, and [11C]MET are excreted in breast milk. Still, for
11C-labeled radiopharmaceuticals, interruption is not essential
due to their short physical half-life. No recommendation
concerning the pause in lactation for 18F-labeled choline ana-
logues is available in ICRP publication 128, but it may be
found in the SmPC of the 18F-labeled choline analogues prep-
aration with a marketing authorization. A 12 h pause is rec-
ommended in some SmPCs.
Qualifications and responsibilities
of personnel
Nuclear medicine physicians, technicians and all other staff
involved in performing and reporting parathyroid radionu-
clide imaging should be qualified according to applicable laws
and regulations, and individual responsibilities should be
clearly documented.
Useful clinical information for optimal
imaging and interpretation
A request for parathyroid radionuclide imaging must be sub-
mitted to a nuclear medicine physician. It should provide suf-
ficient data to allow the responsible nuclear medicine physi-
cian to assess the indication for the scan adequately, as well as
to interpret the images.
The patient is also questioned (if possible) for relevant
information that may help interpret the findings.
In pre-imaging reporting it is useful to document:
1. Serum intact PTH level and either albumin corrected or
ionized calcium and serum 25-hydroxy vitamin D level
(mandatory)
2. Serum phosphorus, 24-h urinary calcium levels, creati-
nine, markers of bone turnover, e.g., bone-specific alka-
line phosphatase (optional)
3. Results of cervical US, including the thyroid and parathy-
roid glands
4. Results of other imaging modalities, such as 4D-CT, and
MRI, if any
5. History of any prior neck and/or thoracic surgery
6. History of malignancy, because of possible tracer accu-
mulation in neoplastic tissue
7. History of recent nuclear medicine procedures
8. Recent iodine intake (e.g., intravenous contrast medium,
iodine-containing medication …) or thyroid hormone re-
placement therapy in case of subtraction study with
Na[99mTc]TcO4 or Na[
123I]I, or therapy with cinacalcet
and other calcimimetics in case of [99mTc]Tc-MIBI
imaging
9. Use of calcium channel blockers if scintigraphy is per-
formed with [99mTc]Tc-MIBI
Patients should be provided with information on how the
examination is performed and the estimated duration. The
patient should be advised to stay calm during image acquisi-
tion. In rare cases, e.g., in patients with severe claustrophobia,
sedation may be helpful.
Patients may eat, drink, and take most of the necessary
medications. However, active D vitamin analogues and
calcimimetics may decrease [99mTc]Tc-MIBI uptake [44]. If
possible, these should be paused for 2 weeks before scintig-
raphy [36].
Calcium channel blockers may reduce uptake of
[99mTc]Tc-MIBI as well [45]. Friedman et al. in a retrospec-
tive study found that the odds ratio for a negative scan is 2.88
in patients taking calcium channel blockers compared with
those without such medication (OR 2.88, 95% CI, 1.03–
8.10; p = 0.045). Still, further studies are necessary to confirm
the reversibility of this finding, and to determine the appropri-
ate withdrawal period.
In a dual-tracer study, the thyroid scan should be performed
without iodine saturation. Many factors can influence thyroid
uptake of subtraction radiopharmaceuticals [46]. Dual-phase
[99mTc]Tc-MIBI scintigraphy, instead of dual-tracer scintigra-
phy, is recommended for patients on thyroid hormone replace-
ment therapy to avoid therapy withdrawal and subsequent
development of hypothyroidism.
Currently, no standardized patient preparation or image
acquisition guidelines exist for parathyroid imaging with
PET tracers. In the case of radiolabelled choline, vigorous
exercise may increase muscle uptake of the radiopharmaceu-
tical, so it is advisable to avoid such before scanning [47].
If a diagnostic CT scan with iodinated contrast medium is
required, it is important to ask the patient about possible aller-
gies to iodinated contrast medium as well as to ascertain an
adequate kidney and thyroid function; for more information,
we advise to consult the European Society of Urogenital
Radiology (ESUR) guidelines on contrast media: Post-
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contrast acute kidney injury—Part 1: Definition, clinical fea-
tures, incidence, role of contrast medium and risk factors;
Post-contrast acute kidney injury—Part 2: risk stratification,
role of hydration and other prophylactic measures, patients
taking metformin and chronic dialysis patients [48, 49].
Scintigraphy and SPECT
Parathyroid gland scintigraphy has involved many different
radiotracers used with different protocols over the past
decades.
In the 1980s, parathyroid gland scintigraphy was per-
formed with [201Tl]thallous-chloride ([201Tl]TlCl) in combi-
nation with [99mTc]Pertechnetate ([99mTc]NaTcO4) as a dual-
tracer method. The success rate in operated patients was com-
parably good, reaching 92% [50]. However, [201Tl]TlCl has
poor physical characteristics as an imaging agent, due to sub-
optimal photon energy (69–81 keV). Additionally, it has a
long physical half-life (73 h) and thus results in a nowadays
unacceptably high whole-body radiation exposure.
[201Tl]TlCl should no longer be used for parathyroid imaging.
Furthermore, it is a cyclotron-produced radionuclide, and as
such relatively expensive. In 1989, Coakley et al. reported the
use of [99mTc]Tc-MIBI for parathyroid localization, revealing
better imaging characteristics of this tracer compared with
[201Tl]TlCl [51]. Eventually, [201Tl]TlCl was replaced with
99mTc-labeled tracers of better physical characteristics: more
favorable energy (140 keV) and shorter physical half-life
(6 h), resulting in lower radiation exposure. Besides, 99mTc
is ubiquitously available and comparatively inexpensive.
More widespread use of [99mTc]Tc-MIBI and [99mTc]Tc-
tetrofosmin began in the 1990s. The former was used in the
single-tracer and dual-tracer methods, while the latter was
used mainly in a dual-tracer method in combination with
Na[99mTc]TcO4 or Na[
123I]I.
Radiopharmaceuticals targeting parathyroid glands
[99mTc]Tc-hexakis-(2-methoxy-2-isobutyl isonitrile) ([99mTc]
Tc-MIBI)
[99mTc]Tc-MIBI is the most widely used radiopharmaceutical
for parathyroid scintigraphy. It is a lipophilic cationic complex
that accumulates in hyperfunctioning parathyroid glands due
to their increased number of mitochondria [52], which is
mainly related to the number of oxyphil cells [53]. Its uptake
and retention depend also on the cell cycle phase, parathyroid
blood supply, capillary permeability, serum calcium level, ex-
pression of P-glycoprotein, and multidrug resistance (MDR)
associated protein [54].
[99mTc]Tc-MIBI has a greater uptake per gram of parathy-
roid tissue than per gram of thyroid tissue [55]. Additionally, it
usually washes out faster from the thyroid than from the hy-
perfunctioning parathyroid, making it convenient for the
single-tracer dual-phase method.
However, not all hyperfunctioning parathyroid glands re-
tain [99mTc]Tc-MIBI and thyroid tissue sometimes does not
rapidly washout [56]. Therefore, in some cases, other proto-
cols might be helpful. In the case of a rapid parathyroid wash-
out, it would be reasonable to perform additional images be-
tween the standard early and late phase ones. Alternatively,
dynamic imaging may be used. On the other hand, in the case
of a slow thyroidal washout, subtraction imaging may be
helpful.
[99mTc]Tc-MIBI SPECT/CT scintigraphy is the current
standard method for detecting hyperfunctioning parathyroid
glands, with a reported patient-based and lesion-based pooled
detection rate (DR) of 88% in a meta-analysis of twenty-three
papers including 1236 patients with pHPT [57]. Furthermore,
it was shown to be a cost-effective technique [58].
However, its sensitivity is significantly lower in the case of
MGD compared with single-gland disease [59, 60], which is a
known issue also with other imaging modalities. Nichols et al.
in a study of 651 patients with HPT (20% with MGD, and
80% with single-gland disease) who underwent preoperative
dual-tracer [99mTc]Tc-MIBI/Na[99mTc]TcO4 scintigraphy
found the sensitivity of this method to be 61% for MGD, vs.
97% for single-gland disease [60]. Medas et al. in a study that
included 212 patients with HPT (8% with MGD, 91.5% with
single-gland disease, and 0.5% unknown) reported a sensitiv-
ity of [99mTc]Tc-MIBI for MGD of 26.7% vs. 92.6% for
single-gland disease [59].
The administered intravenous radioactivity in adults ranges
from 400 to 900 MBq, depending on the patient’s body mass,
whether or not SPECT is scheduled, and local regulations
(Table 1). Whenever SPECT imaging is combined with CT,
care should be taken to use the lowest CT dose that is com-
patible with the purpose.
[99mTc]Tc-1,2-bis[bis (2-ethoxyethyl) phosphino] ethane)
([99mTc]Tc-tetrofosmin)
[99mTc]Tc-tetrofosmin is a lipophilic cation that localizes in
thyroid and parathyroid tissue. Because there is no differential
washout between these tissues, it is suitable only for a dual-
tracer subtraction method. The mechanism of uptake is similar
to [99mTc]Tc-MIBI. It diffuses passively through the cell
membrane and accumulates in mitochondria of parathyroid
lesions [61]. The intravenously administered activity in adults
ranges from 400 to 900MBq, depending on the patient’s body
mass, whether or not SPECT is scheduled, and local
regulations.
However, its use in parathyroid imaging is limited, despite
an overall good performance similar to that of [99mTc]Tc-
MIBI [56, 62, 63], owing, e.g., to the need for the dual-
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99mTc has a physical half-life of 6 h and emits gamma rays of
140 keV. Na[99mTc]TcO4 is used in the dual-tracer method as
i t is taken up by funct ioning thyroid cel ls . The
Na[99mTc]TcO4 image is subtracted from the [
99mTc]Tc-
MIBI / [99mTc]Tc-tetrofosmin image, thus revealing hyper-
functioning parathyroid glands.
For further details on administered activity and image ac-
quisition, please refer also to the EANM practice guideline/
SNMMI procedure standard for RAIU and thyroid scintigra-
phy [46]. The administered activity depends mainly on which
tracer is applied first, i.e., if the thyroid study is performed
before or after the [99mTc]Tc-MIBI / [99mTc]Tc-tetrofosmin
scan. If imaging starts with Na[99mTc]TcO4 scintigraphy, low-
er activities are required, i.e., 74–111 MBq compared with
150 MBq if the thyroid scan is performed after the
[99mTc]Tc-MIBI scan.
[123I]sodium-iodide (Na[123I]I)
123I has a half-life of 13 h and emits gamma radiation of
159 keV. Na[123I]I is trapped but also organified by function-
ing thyroid tissue. Na[123I]I is used in the dual-tracer method
for subtraction purposes and provides good quality images.
The Na[123I]I image is subtracted from a [99mTc]Tc-MIBI /
[99mTc]Tc-tetrofosmin image for easier visualization of re-
maining hyperfunctioning parathyroid gland tissue.
Disadvantages are its higher price compared with
Na[99mTc]TcO4 and the 2 h waiting time between administra-
tion of the radiopharmaceutical and acquisition of the scan.
For further information on this radiopharmaceutical, we refer
to the EANM practice guideline/SNMMI procedure standard
for RAIU and thyroid scintigraphy [46].
Acquisition
Dual-phase parathyroid scan
[99mTc]Tc-MIBI scintigraphy is performed at two time points,
i.e., at 10–15 min and 90–150 min after intravenous adminis-
tration of the radiopharmaceutical. The administered activity
ranges from approximately 400 to 900 MBq, depending on
the patient’s body mass, whether or not SPECT is scheduled,
and local regulations. Imaging is performed using large field-
of-view gamma cameras with low-energy, high resolution
(LEHR) collimators. The energy window should be in the
range of 140 ± 10 keV and a matrix size of 128 × 128 or better
256 × 256 should be employed. The entire neck and the chest
down to the base of the heart should be included in the field of
view. It is possible to use planar images in anterior and right
and left anterolateral positions, but SPECT images, especially
when fused with a simultaneously acquired CT, are superior
for anatomical localization of parathyroid tissue [64], espe-
cially in case of ectopic glands and altered neck anatomy [65].
SPECT/CT with [99mTc]Tc-MIBI is superior to planar or
stand-alone SPECT studies and dual-phase acquisition is more
accurate than single-phase acquisition [66]. Therefore, it is
recommended to perform at least one SPECT(/CT) study cov-
ering the area between the skull base and the heart base.
Dual-tracer parathyroid scan
[99mTc]Tc-MIBI usually has a differential washout between
the thyroid and parathyroid, so it is used as the single tracer of
dual-phase parathyroid scintigraphy in many nuclear medi-
cine departments. However, sometimes the tracer washes out
rapidly from the parathyroid or is retained in the thyroid, es-
pecially in thyroid nodules. In such cases, the use of the dual-
tracer method may be helpful.











Effective dose for the upper
administered activity (mSv)
Na[99mTc]TcO4 i.v. 74–150 140 6.04 h 0.0159* 2.4
[99mTc]Tc-MIBI i.v. 400–900 140 6.04 h 0.00703* 6.3
[99mTc]Tc-tetrofosmin i.v. 400–900 140 6.04 h 0.00629* 5.7
Na[123I]I o.a. (or i.v.) 7.4–14.8 159 13.2 h 0.108* (thyroid uptake
15%)
1.6 (thyroid uptake 15%)
[18F]FCH i.v. 100–300 511 110 min 0.020** 6.0
[11C]MET i.v. 370–1100 511 20.3 min 0.00549* 6.0
[11C]CH i.v. 200–650 511 20.3 min 0.0044*** 2.9
i.v., intravenous; o.a.,oral administration,* [163],** [164],*** [165]
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Dual-tracer [99mTc]Tc-MIBI /Na[99mTc]TcO4 protocol Either
tracer, [99mTc]Tc-MIBI or Na[99mTc]TcO4 can be injected
first. The administered activity of Na[99mTc]TcO4 is 74–
111 MBq if the protocol starts with thyroid imaging. For fur-
ther details, please refer to the EANM practice guideline/
SNMMI procedure standard for RAIU and thyroid scintigra-
phy [46]. 150 MBq of activity is used if thyroid imaging is
performed after the [99mTc]Tc-MIBI scan.
Na[99mTc]TcO4 images are obtained 20–30 min after ad-
ministration of the radiopharmaceutical, while [99mTc]Tc-
MIBI images are obtained 10–15 min after injection. Images
are inspected visually, normalized, and Na[99mTc]TcO4 im-
ages are either digitally or cognitively subtracted from the
[99mTc]Tc-MIBI images. The following images are obtained:
- a large field of view of the neck and mediastinum (from the
skull base to the heart base); − a pinhole view of the thyroid
bed region; and a SPECT(/CT) acquisition whenever
available.
In order to reduce administered activities and radiation ex-
posure, a waiting time of 2–3 days between tracers may be
recommended.
Imaging is performed using a large field-of-view gamma
camera with LEHR collimators, a matrix size of 128 × 128 or
256 × 256, and a 15% or 20% energy window centered at the
140 keV (99mTc) photon peak.
Dual-tracer [99mTc]Tc-MIBI / Na[123I]I protocolNa[123I]I is first
administered orally or intravenously, and [99mTc]Tc-MIBI is
injected 2 h later. Na[123I]I and [99mTc]Tc-MIBI images are
acquired simultaneously, starting 5 min after injection of
[99mTc]Tc-MIBI. Images are inspected visually, normalized
to thyroid counts, and Na[123I]I images are subtracted from
the [99mTc]Tc-MIBI images. The following images are obtain-
ed: - a large field of view of the neck and mediastinum (from
the skull base to the heart base); − a pinhole view of the
thyroid bed region; − a SPECT(/CT) acquisition when avail-
able [67–69].
Imaging is performed with a large field-of-view gamma
camera equipped with LEHR collimators. A matrix size of
128 × 128 or 256 × 256 is recommended. For simultaneous
acquisition, a 10% energy window centered on the 159 keV
is recommended for Na[123I]I and a 15–20%window centered
around 140 keV for [99mTc]Tc-MIBI. Alternatively, symmet-
ric and asymmetric windows can be used (140 keV ± 7% for
[99mTc]Tc-MIBI and 159 keV −4%; +10% for Na[123I]I) [70].
For Na[123I]I thyroid imaging, it is also possible to use a
dedicated thyroid camera with a small field-of-view.
In both dual-tracer protocols images are subtracted at the
point of similar activity of [99mTc]Tc-MIBI in the thyroid
gland and surrounding soft tissue.
Dual-tracer scintigraphy with subtraction imaging has an
excellent performance in the detection and localization of hy-
perfunctioning parathyroid glands [71]. Woods et al. in a
recent study reported high sensitivity and specificity for sub-
traction SPECT/CT (95% and 89%, respectively) [72]. The
positive predictive value (PPV) and negative predictive value
were 97% and 83%, respectively. The accuracy in detecting
and localizing parathyroid adenomas were 94% and 92%,
respectively. However, this technique adds additional radia-
tion exposure to the thyroid; it might take additional time and
is more expensive compared with a single-tracer method, al-
though some institutions are trying to reduce administered
activity and procedure length.
Image analysis
In dual-phase scintigraphy, early and delayed images are
inspected visually. Increased or sustained uptake on the de-
layed [99mTc]Tc-MIBI image, compared with the early image,
is considered a positive finding for a hyperfunctioning para-
thyroid gland. However, some glands show a fast washout and
might not be identified clearly on delayed images. A fast
clearance is more common in hyperplastic glands. SPECT
images may reveal parathyroid glands that are not seen on
planar images. Additionally, SPECT/CT imaging provides a
superior anatomic localization of lesions.
In subtraction scanning, images need to be inspected visu-
ally before and after subtraction. Focal accumulation of radio-
pharmaceutical adjacent to the thyroid persisting after subtrac-
tion is suspicious for a hyperfunctioning parathyroid gland in
loco typico; ectopic focal uptake is suspicious for an ectopic
parathyroid lesion. As stated above, SPECT and SPECT/CT
yield an increased sensitivity, specificity, and more precise
anatomic localization compared with planar images.
The CT part of the study should be also analyzed for im-
portant findings, even without corresponding tracer uptake.
False-positive and false-negative results are occasionally
encountered. The most common causes of false-positive re-
sults are inflammatory thyroiditis, cervical lymphadenopathy,
and thyroid nodules (benign and malignant) behaving like
parathyroid adenomas (in a single-tracer protocol) [73].
False-negative results usually occur due to small-sized hyper-
functioning glands [73], a lack of oxyphil cells [74], parathy-
roid hyperplasia, multiglandular disease, and high expression
of P-glycoprotein [75].
Positron emission tomography
The higher resolution of PET/CT imaging could improve the
detection of the smallest pathological glands, not visualized
by SPECT(/CT). It is recommended to use the scanner with
the highest system sensitivity and reconstruction protocols
optimized for small lesion detection (BSREM instead of
OSEM). Whenever PET imaging is combined with CT, care
should be taken to use the lowest CT dose that is compatible
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with the purpose. Several different tracers have been studied
with different protocols and results.
Currently, no standardized image acquisition guidelines
exist for PET tracers for parathyroid imaging.
Radiopharmaceuticals
18F-labeled choline analogues
Choline is a cellular proliferation marker. The mechanism of
uptake of 18F-labeled or 11C-labeled choline analogues is not
fully understood. As choline is a precursor of phosphatidyl-
choline, a phospholipid constituent of the cell membrane, its
uptake, and processing for construction and maintenance of
the cell membrane is a possible explanation for its accumula-
tion in hyperfunctioning parathyroid glands [76, 77].
Stimulation of phospholipid-dependent choline-kinase results
in increased radiolabeled choline uptake and is related to the
secretion of PTH in HPT [78].
A commonly used choline analogue in clinical practice is
( N - [ ( 1 8 F ) f l u o r o m e t h y l ] - 2 - h y d r o x y - N , N -
dimethylethanaminium ([18F]FCH or [18F]fluorocholine).
Other similar radiofluorinated choline derivatives are also
available and supposedly show similar clinical behavior and
utility. Administered activity ranges from 100 to 300 MBq or
1.5–3.2MBq/kg of bodymass. According to the study by Rep
et al., the recommended imaging time is one hour after the
administration of the radiopharmaceutical, and, if possible,
preceded by imaging acquired 5 min after the injection
(starting as dynamic acquisition and followed by static), as
some lesions may show uptake in the early phase only [79].
One acquisition 20 min after injection with delayed images in
case of a negative result is also an option [40]. The field of
view can be limited from the nose to the chest down to the
base of the heart as for scintigraphy, to obtain a low radiation
exposure from CT. But thanks to the more rapid acquisition
with PET than with SPECT it may easily be extended to the
whole torso or the whole body according to the patient’s his-
tory (neoplasia, skeletal disease, infection…) or incidental
findings. On PET/CT machines with incremental acquisition
and time of flight imaging, at least 2 min per bed position may
be recommended. PET/CT with 18F-labeled choline ana-
logues yields promising results, with DRs exceeding 90%.
Treglia et al. in a meta-analysis of 14 choline studies (con-
taining 12 studies with 18F-labeled and 2 with 11C-labeled
choline derivatives) involving 517 patients, reported pooled
values for the sensitivity of 95%, PPV 97%, and DR 91% on a
per-patient analysis. In a per-lesion analysis, the pooled sen-
sitivity was 92% and PPV was 92% [78].
In addition, Hocevar et al. in a recent study demonstrated
that patients with a single adenoma on [18F]fluorocholine
PET/CT can safely and accurately undergo minimally inva-
sive parathyroidectomy without intraoperative PTH testing
[80]. Preoperative localization was reliable in 96.8% of
patients.
In a recent head to head comparative study including 103
patients with pHPT, the diagnostic performance of
[18F]fluorocholine PET/CTwas superior to conventional scin-
tigraphic methods ([99mTc]Tc-MIBI SPECT/CT, [99mTc]Tc-
MIBI / Na[99mTc]TcO4 subtraction imaging, and [
99mTc]Tc-
MIBI dual-phase imaging), separately or combined, with a
sensitivity of 92% for [18F]fluorocholine PET/CT, compared
with 39–56% for conventional imaging, and 65% for a com-
bination of conventional methods [81]. The impact of the
performance of the PET/CT machine on the performance of
[18F]fluorocholine imaging in patients with negative or incon-
clusive [99mTc]Tc-MIBI SPECT/CT has been recently
assessed by Lopez-Mora et al. [82]. In a prospective series
of 33 patients with pHPT confirmed at surgery, they found
that [18F]fluorocholine PET/CT employing an analogic scan-
ner could detect hyperfunctioning tissue in 22 of 33 of patients
with negative or inconclusive [99mTc]Tc-MIBI SPECT/CT,
while a digital scanner detected hyperfunctioning tissue in
30 of 33 patients. The lesions detected only by the digital
system were < 10 mm in diameter on resection, highlighting
the potential importance of new PET/CT technologies in the
detection of small parathyroid lesions.
Other advantages of PET/CT with 18F-labeled choline an-
alogues over [99mTc]Tc-MIBI scintigraphy are the lower radi-
ation exposure [83], the higher resolution, and the shorter
acquisition time. It is therefore considered an alternative
first-line imaging method [84, 85].
Potential disadvantages of PET/CT with 18F-labeled cho-
line analogues are higher costs, the uptake by inflammatory
lymph nodes and thyroid nodules as a potential source of
false-positive results [86], and local reimbursement and li-
censing issues.
18F-labeled choline analogues may be also used in PET/
MRI systems. This novel method is promising in patients with
inconclusive results of standard imaging techniques [87].
[11C]2-hydroxy-N,N,N-trimethylethanamium ([11C]CH)
As mentioned above, choline is a precursor of phosphatidyl-
choline, which may explain the fact that [11C]CH shows
strong uptake in hyperfunctioning parathyroid cells [76].
Noltes et al. tried to optimize the protocol for [11C]CH
PET/CT imaging, taking into consideration the activity and
image quality [88]. They retrospectively studied 21 patients
with pHPT and suggested image acquisition 20min after ad-
ministration of 6.3MBq/kg [11C]CH, with a scanning time of
at least 5 min. Orevi et al. in a prospective pilot study includ-
ing 40 patients with pHPT indicated that [11C]CH provides
higher image quality than [99mTc]Tc-MIBI, with the same or
even superior diagnostic accuracy [89].
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The advantage of [11C]CH PET/CT over scintigraphy is a
shorter acquisition time. There is fast uptake of [11C]CH in
hyperfunctioning parathyroid tissue, as well as a rapid clear-
ance of background activity. Imaging is completed within
30 min. In addition, the radiation exposure is lower. The short
physical half-life of 11C (20.3 min) results in significantly
lower radiation exposure than using a 18F-labeled choline an-
alogue, as well as other nuclear medicine techniques and 4D-
CT.
On the other hand, the short physical half-life is a draw-
back, restricting the use of 11C to facilities with an on-site
cyclotron. Additionally, a higher average positron energy of
11C leads to more noise on the images and poorer spatial
resolution compared with 18F.
L-[methyl-11C]methionine ([11C]MET)
[11C]MET is a PET radiopharmaceutical that was previously
often used as a second-line imaging tracer after negative or
inconclusive conventional imaging. It is trapped in the hyper-
functioning parathyroid gland as it is involved in the synthesis
of the PTH precursor [90]. The administered activity of the
radiopharmaceutical varies between 370 and 1100 MBq in
different [11C]MET studies. Reported acquisition time is also
highly variable, ranging from a start immediately after to
40 min after injection. In most studies, PET scanning is pre-
ceded or followed by a low-dose CT scan. Some authors rec-
ommend imaging at two time points, 10 min and 40 min after
application of the radiopharmaceutical, preceded or followed
by CT scanning for attenuation correction [90, 91]. The best
parathyroid to cervical soft-tissue ratio was accomplished
10 min and the best parathyroid to thyroid ratio 40 min after
administration of the radiopharmaceutical [90].
Increased uptake at early or late imaging is considered
positive.
Kluijfhout et al. in a meta-analysis of 14 [11C]MET studies
found a pooled sensitivity of 77% and a pooled PPV of 98%
for the detection of hyperfunctioning parathyroid glands in the
correct quadrant [92]. There was no difference in sensitivity in
patients with and without previous negative or inconclusive
standard imaging (81% vs. 78%, respectively). However,
Noltes et al. in a recent retrospective study found that
[11C]MET PET/CT is able to identify parathyroid lesions on
the correct side in only 64% (18/28) of patients after prior
negative [99mTc]Tc-MIBI SPECT/CT and/or cUS [93].
Weber et al. prospectively studied whether [11C]MET
PET/CT is able to identify [99mTc]Tc-MIBI-negative hyper-
functioning parathyroid glands in a cohort of 50 pHPT pa-
tients [94]. Pre-surgical scanning with [11C]MET PET/CT lo-
calized hyperfunctioning parathyroid glands in 74% of pa-
tients with negative [99mTc]Tc-MIBI scintigraphy.
[11C]MET PET/CT detected 40 out of 57 (70%) hyperfunc-
tioning glands.
The major limitations of this radiopharmaceutical for more
widespread use are the short physical half-life of 11C
(20.3 min) which necessitates an on-site cyclotron, the de-
manding labeling process which requires an on-site
radiopharmacy with competent radiochemical staff, and a
higher average positron energy which leads to more noise
compared with 18F. Additionally, there are local reimburse-
ment and licensing issues.
Other PET tracers
Other PET tracers are not recommended for the detection of
hyperfunctioning parathyroid glands, based on currently pub-
lished data. 18F-fluoro-D-glucose ([18F]FDG) is almost ubiq-
uitously available and has the advantage of possible off-site
usage due to a significantly longer physical half-life of 18F
(110 min) compared with 11C. However, sensitivity and
PPV vary considerably between the few available studies,
0–94% and 62–100%, respectively. Therefore, this tracer does
not seem suitable for the detection of hyperfunctioning para-
thyroid glands compared with other standard imaging tech-
niques [92]. However, sometimes incidental parathyroid ade-
nomas may be detected in [18F]FDG studies acquired for other
reasons than HPT. 3,4-dihydroxy-6-[18F]fluoro-L-phenylala-
nine (6-[18F]F-DOPA) does not appear promising, as reported
by Lange-Nolde et al. [95]. These authors scanned 8 patients
with pHPT and histologically proven parathyroid adenomas,
but none of the patients showed any detectable uptake of
6-[18F]FDOPA in adenoma. O-(2-[18F]fluoroethyl)-L-tyro-
sine ([18F]FET) also does not appear to be promising as re-
ported by Krakauer et al. [96]. In two patients, dual-isotope
SPECT/CT located a parathyroid adenoma, verified by histo-
pathology; only faint uptake of [18F]FET was detected in the
hyperfunctioning parathyroid glands. Themaximum (but low)
target-to-background ratio was reached 30 min after tracer
administration.
Image analysis
The reading of PET/CT or PET/MRI to localize hyperfunc-
tioning parathyroid gland(s) usually starts with visualizing
multiple intensity projections which may show foci behind
the thyroid gland and help in detecting ectopic foci. The anal-
ysis of attenuation-corrected slices in the 3 planes with and
without CT (orMRI) fusion is necessary in all cases, to precise
the anatomical landmarking and the size of abnormal foci. The
analysis of non-attenuation-corrected images may sometimes
be useful in the case of artifacts on CT or of incidental foci in
the lungs. For the neck region, the soft-tissue CT window
should be used. A reading of PET and PET/CT (MRI) fused
images of organs or structures out of the neck but included in
the whole field of view, should not be omitted. The soft-tissue
CT window is adapted to the mediastinum and the breasts
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(and the liver in the absence of a specific window), but other
CT windows are recommended for lung and bone (and liver if
this window is available).
All foci located from the upper neck to the base of the
heart with an increased tracer uptake compared with the
adjacent background should be considered. Focal accumu-
lation of radiopharmaceutical in a nodule next to the thy-
roid is suspicious for a hyperfunctioning parathyroid
gland in the loco typico. A hypodense character compared
with the thyroid parenchyma on CT and a SUVmax great-
er than that of the thyroid parenchyma are further argu-
ments favoring this interpretation [35]. In the case of
dual-time point acquisition, the persistence in the late im-
ages of foci visible on the early images is a further argu-
ment in the case of equivocal early findings, but the dis-
appearance of an evocative focus on early images could
be due to a hyperfunctioning parathyroid gland with rapid
clearance of the tracer. Even though the thyroid uptake of
choline-based tracer is usually moderate, it is diffusely
intense in case of thyroiditis or of Graves’ disease, mak-
ing the detection of foci adjacent to the thyroid gland
difficult. The main interpretation problem is a focal tracer
uptake inside the thyroid which corresponds in most cases
to a malignant or benign thyroid nodule (in particular
oxyphil adenomas are [18F]FCH avid) but may also cor-
respond to an intrathyroidal parathyroid gland [35]. In
methionine studies, thyroid nodules may also cause
false-positive results [93]. In case of thyroid anomalies,
it is recommended to analyze the PET/CT images with
reference to thyroid scintigraphy (with Na[123I]I if avail-
able) to check how PET/CT foci match with the location
and the iodine-metabolism of thyroid nodules; maximum
intensity projection and coronal slices are particularly use-
ful in this aim. Small thyroid remnants in case of partial
or total thyroidectomy may take up the PET tracer leading
to a false-positive result which may be avoided by refer-
ring to thyroid scintigraphy. Concerning the interpretation
of ectopic foci, the main pitfall with metabolic tracers is
uptake by reactive lymph nodes. In particular [18F]FCH is
very frequently taken up by mediastinal and/or axillary
lymph nodes which are not suspicious for ectopic para-
thyroid glands. Uptake by one single cervical lymphade-
nopathy may constitute a problem for interpretation [86].
The analysis of the CT (or MRI) component yields a more
precise anatomical localisation and may also increase
specificity.
False-negative results in choline/methionine studies may
occur in cases of moderate hypercalcemia and non-elevated
PTH serum levels (so-called “abnormally normal serum PTH
level). In the case of MGD, one or several hyperplastic glands
may be missed, particularly in sHPT or MEN. False-negative
results may also be caused by a too restricted field of view, in
particular in case of recurrence after parathyroidectomy.
Reporting parathyroid radionuclide imaging
The scan report should include patients’ relevant identifying
data as well as the relevant clinical history including serum
PTH and calcium levels and any further relevant details, such
as a history of MEN or history of (para)thyroid surgery.
The report should include a technical section, mentioning
the protocol employed, the tracer(s) used together with admin-
istered activities and route of administration, which images
were acquired (planar projections, SPECT/CT, PET/CT,
PET/MRI, including the anatomic area), the dose-length prod-
uct if CT has been acquired, and their respective timing and, if
relevant, details on image reconstruction.
Reports need to include at least the description of abnormal
findings (one or more hyperfunctioning parathyroid lesions)
and localization of abnormal gland(s) expressed in terms of
the four thyroidal quadrants including the gland(s) depth, or
the particular ectopic location, as well as the images in which
these are identified. Detection of a hyperfunctioning parathy-
roid gland with [99mTc]Tc-MIBI, whose implantation in the
forearm had not been recorded, was reported [97].
Additionally, one should document any incidental finding,
such as pathological [99mTc]Tc-MIBI uptake in the pituitary
region (if included in the field of view) [98], or in the lungs
[99], or 18F-labeled choline analogues foci suspicious for ma-
lignancy [100, 101], which should prompt further diagnostic
investigation. A frequently abnormal bone uptake of
[99mTc]Tc-MIBI has been reported by Zhao et al. in 22
(27.8%) patients [102]. Nineteen of them showed diffusely
increased activity in the skeleton, 2 patients had focal uptake
in brown tumors, and one showed both of these patterns.
Brown tumors, also known as osteitis fibrosa cystica, are a
specific complication of HPT, mostly in the case of sHPT or
prolonged pHPT, or parathyroid carcinoma. They are usually
multiple, but also a solitary lesion may be present [103]. On
CT, brown tumors appear as lytic or multilobular cystic
changes. They may be detected with 18F-labeled choline ana-
logues whereas [99mTc]Tc-MIBI is negative [104]. In the case
of incidental bone foci, this etiology may be considered as
well as primary or secondary bone malignancies [105–107].
Diffuse and intense tracer uptake in the jaw may be observed
in rare cases, being evocative of HPT-jaw tumor syndrome, a
genetic disease linked with a negative prognosis [108–110].
Cervical ultrasonography
It is recommended to perform cUS in conjunction with nuclear
medicine imaging. Cervical ultrasonography is often used for
parathyroid gland localization. It is also utilized for
confirming the diagnosis of the hyperfunctioning parathyroid
gland(s) by guided FNA cytology and analysis of the FNA-
PTH in highly selected cases. It also provides an additional
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evaluation of the thyroid that may change surgical manage-
ment, especially in the case of coexisting (suspected) malig-
nant nodules [111].
Cervical ultrasonography is a low-cost, non-invasive (apart
from guided FNA), accurate, and highly sensitive technique in
experienced hands [112].
It is performed with the patient in a supine position with a
hyperextended neck, using a high-frequency (≥ 7 MHz) linear
transducer. It is recommended to perform cross-sectional and
longitudinal images of the anterior neck region, between the
common carotid arteries, from the level of the carotid bifurca-
tion down to the superior mediastinum, particularly paying
attention to the posterior surface of the thyroid and the region
below it. The size and location of the thyroid, thyroidal lesions,
and any suspected parathyroid glands should be carefully doc-
umented. Owing to their small size (approximately 3 to 5 mm),
normal parathyroid glands are usually not identified on cUS.
Hyperfunctioning parathyroid glands are detectable due to their
size and echogenicity. They are usually hypoechoic,
circumscribed, ovally shaped, delineated from the thyroid by
hyperechoic connective tissue. However, they may have vari-
ous shapes and contain fluid and, rarely, calcifications. Some
glands have undergone cystic degeneration, presenting as an-
echoic lesions with dorsal echo amplification. Sometimes, a
peripheral artery branching into the gland can be seen.
Occasionally it may be difficult to differentiate enlarged
parathyroid glands from lymph nodes [33].
Cheung et al. in a meta-analysis of 19 studies found that cUS
has a pooled sensitivity of 76.1% and a PPV of 93.2% in the
preoperative localization of enlarged parathyroid glands in pHPT
patients [113]. The diagnostic accuracy of ultrasound may be
improved when performed after radionuclide imaging [114].
Cervical ultrasonography also has some limitations. It can-
not detect ectopic parathyroid glands below the neck level VI
and is less sensitive in the detection of small glands or MGD.
Ruda et al. in a systematic review of 20,225 cases of pHPT
found that the sensitivity of cUS in patients with two adeno-
mas was 16.2% and in MGD 34.9%, compared with 78.5% in
single-gland disease [115]. Medas et al., in a retrospective
study of 212 patients, also reported lower cUS sensitivity in
patients with MGD compared with patients with single-gland
disease (18.7% and 66.5%, respectively) [59]. Haciyanli et al.
reported accuracy of cUS of 40% in patients with two adeno-
mas, while the combination of cUS and [99mTc]Tc-MIBI
yielded an accuracy of 60% [116].
False-negative results also occur with an intrathyroidal lo-
cation of hyperfunctioning parathyroid glands, being
misinterpreted as thyroid nodules. Fine-needle aspiration cy-
tology accompanied by the measurement of the FNA-PTH
may solve this diagnostic challenge [117]. Furthermore, en-
larged parathyroid glands adjacent to the upper thyroid poles
may have a similar echogenicity as the thyroid gland and
might hence be missed [112].
Medas et al. reported a lower sensitivity in patients with
concomitant thyroid disease compared with patients with nor-
mal thyroid tissue (46.7% vs. 75%) [59]. Thyroid nodules are
a common reason for false-positive results, especially if locat-
ed posteriorly [118]. This is an important issue since synchro-
nous thyroid pathology is common in pHPT patients (18% as
reported by Bentrem et al.) [119].
For the reasons stated above, and since it is an operator-
dependent technique, it is recommended to combine cUS with
parathyroid scintigraphy [73].
For FNA-PTH, a sensitivity of 70–100%, and a specificity
of 75–100% has been published, rendering it more reliable
than cytology alone [120]. However, Trimboli et al. have
shown that despite satisfactory results reported, this procedure
is not widely used because it is not well standardized from pre-
to post-analytical aspects. There is no consensus with regard
to the FNA-PTH reference range and upper cut-off value.
Some authors consider any FNA-PTH positive that is above
the serum PTH level [121–124], whereas others suggest an
FNA-PTH/serum PTH ratio of ≥ 2:1 in order to minimize the
influence of sample contamination by blood [120].
However, in the case of non-diagnostic or indeterminate
cytology findings, FNA-PTH might be useful.
Fine-needle aspiration may harbor complications, such as
post-FNA fibrosis of the parathyroid gland and surrounding
structures, making surgery more difficult and time-consuming
[125]. It may also cause bedeviled histopathology by imitating
malignancy. Norman et al. conducted a study that included 30
patients who underwent FNA of a parathyroid adenoma and a
control group of 3000 patients who underwent surgery with-
out previous FNA. On histopathology, adenomas in the con-
trol group showed a fibrotic reaction in 4.3% of cases, while
glands with previous FNA had a fibrotic reaction in 77% of
cases. The fibrotic reaction also imitated malignancy on his-
topathology. Additionally, the fibrotic reaction was more
common with repeated FNA passes. Fine-needle aspiration
was associated with a doubling of the surgery time [125].
Rarely, FNA may cause an inflammatory reaction, parathy-
roid abscess, or hematoma [126]. Very rare complications of
FNA include parathyromatosis [127, 128] and the potential
risk of parathyroid carcinoma seeding [129, 130]. For the
reasons stated above, FNA cytology is recommended only
in highly selected cases, e.g., atypical cUS findings, or incon-
clusive scintigraphy.
Computed tomography
Standard X-ray CT has limited value in the detection of en-
larged parathyroid glands in pHPT [112].
Four-dimensional CT (4D-CT) consists of standard CT im-
aging with 3 vascular phases (non-enhanced, arterial, and ve-
nous), and the fourth dimension that allows enhancement
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evaluation over time [131, 132]. Hence, this technique also
provides functional data on enlarged parathyroid glands. Fast
uptake and washout of contrast are considered typical for
parathyroid adenomas [73].
This technique has similar diagnostic performance com-
pared with [99mTc]Tc-MIBI SPECT [112], although protocols
vary among institutions, which results in minor differences in
DRs [133–135].
4D-CT has the advantage of short imaging time and is
promising for the detection of small and ectopic parathyroid
glands, but its drawbacks are comparably high radiation ex-
posure and the need for iodinated contrast medium. The dose
of radiation delivered to the thyroid is considerably higher
than with standard imaging methods. Mahajan et al. reported
a 57 times higher (92.0 vs. 1.6 mGy) thyroid dose compared
with [99mTc]Tc-MIBI SPECT imaging [136]. As this at least
in theory results in an increased risk for thyroid malignancies,
this method should be used with caution, especially in youn-
ger patients. Some institutions perform fewer acquisitions to
reduce radiation exposure. However, this in turn leads to a
reduction in sensitivity. Kluijfhout et al. in a meta-analysis
of 34 studies (2563 patients) found a lower pooled sensitivity
of a single-contrast phase protocol (71%), compared with 2-
and 3-contrast phase protocols (76% and 80%, respectively)
[137]. They suggested that a 2-contrast phase protocol is suf-
ficient with regard to sensitivity and radiation exposure.
4D-CT is useful in the case of negative previous imaging
studies or in patients with distorted neck anatomy. It is a good
method for the preoperative detection of hyperfunctioning
parathyroid glands after the unsuccessful initial surgery.
Mortenson et al. in a prospective study of 45 patients who
underwent parathyroid reoperation, revealed a higher sensitiv-
ity of 4D-CT compared with [99mTc]Tc-MIBI SPECT/CT and
neck US (88%, 54%, and 21% respectively) [138].
Combined [18F]fluorocholine PET and 4D contrast-
enhanced CT (4DCeCT) may be considered in pHPT patients
with negative or inconclusive first-line imaging, as stated by
Piccardo et al. [135]. They prospectively enrolled 44 pHPT
patients. [18F]fluorocholine PET/4DCeCT was positive in 32
of 44 patients with pHPT (72.7%), and in 31 of 31 operated
patients (100%), being superior to [18F]fluorocholine PET/CT
alone (80% and 56.8%, respectively) and 4DCeCT alone
(74% and 54.5%, respectively).
However, the reported sensitivity of CT for a MGD is still
as low as 32–53% [139].
Magnetic resonance imaging
Hyperfunctioning parathyroid glands may have variable MRI
characteristics. However, they usually show intermediate to
low signal intensity on T1-weighted images and high signal
intensity on T2-weighted images [140].
Lopez Hänninen et al. in 2000 reported a high sensitivity of
MRI for identifying hyperfunctioning parathyroid glands
[141]. 1.5-T MRI detected 32 out of 39 surgically proven
abnormal parathyroid glands (82%). Sensitivity was higher
for adenomas compared with hyperplasia (87% and 75%,
respectively).
Wakamatsu et al. in a study from 2003, involving 35 pa-
tients with pHPT and 4 with sHPT, reported an unsatisfactory
overall MRI sensitivity for the detection of hyperfunctioning
parathyroid glands (43.4%) [142]. There were 29 patients with
the single-gland disease and 10 withMGD. The sensitivity for
the first group was slightly higher (48.3% vs. 37.5%, respec-
tively). However, they used a 0.5 T MRI, which may influ-
ence sensitivity.
A recent study by Argirò et al. demonstrated the correct
localization of hyperfunctioning parathyroid glands in 45/46
patients that underwent 3 T MRI with standard clinical pulse
sequences, yielded an excellent preoperative diagnostic per-
formance, with a sensitivity of 97.8% and a specificity of
97.5% [143]. Furthermore, it showed a good performance in
MGD (8/8 enlarged glands detected) and ectopic parathyroid
lesions (6/7 glands detected).
Merchavy et al. in a study from 2016 reported that 4DMRI
is a useful technique for the preoperative detection of parathy-
roid lesions [144]. In 10 out of 11 patients with parathyroid
lesions, 4D MRI localized adenomas correctly. The reported
sensitivity was 90%, and 100% after optimizing the imaging
time. The specificity was 100%.
Nowadays, MRI is mostly used as a second-line imaging
technique.
While the use of gadolinium-based contrast agents is typi-
cally necessary, MRI does not carry any radiation exposure,
which is a significant advantage of this technique. MRI is also
used as part of PET/MRI exams with 18F-labeled choline an-
alogues and is considered particularly useful for the detection
of cystic adenomas with comparably low tracer uptake [145,
146].
The use of MRI is limited in patients with kidney failure (if
contrast medium is used) and implanted medical devices, such
as cardiac pacemakers. Both kidney failure and cardiac ar-
rhythmia are associated with HPT [76]. Furthermore, it may
also be difficult for MRI to differentiate hyperfunctioning
parathyroid glands from lymph nodes [142].
Further larger studies are necessary to confirm the diagnos-
tic performance of MRI in this setting.
Invasive diagnostic procedures
Invasive diagnostic procedures are used in case of prior un-
successful parathyroid surgery and negative or equivocal non-
invasive imaging studies. They are rarely utilized nowadays
due to improved standard non-invasive imaging and because
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they carry certain risks for the patient. Invasive techniques are
associated with complications such as hematoma, contrast-
induced nephropathy, and cerebrovascular infarction [73].
Anaphylaxis due to an allergic reaction to an iodinated con-
trast medium is an additional complication, also observed in
non-invasive imaging (CT). Thus, invasive techniques should
be performed by a highly experienced operator.
Selective venous sampling
Selective venous sampling is the most commonly utilized
technique. Serial blood samples are obtained from the superior
vena cava, bilateral brachiocephalic, internal jugular, verte-
bral, thymic, superior, middle, and inferior thyroid veins
[73]. An increase in PTH level from the vein drainage sites
is compared with a peripheral sample. Ibraheem et al. in a
recent meta-analysis of 12 studies found a pooled sensitivity
and specificity of 74% and 41%, respectively [147]. This
method had a higher pooled sensitivity compared with non-
invasive methods, mainly US and SPECT tracers, in re-
operated patients.
Selective arteriography
Selective arteriography can be useful in patients with altered
venous drainage due to prior neck surgery [73]. It is performed
by selective transarterial induction of hypocalcemia in combi-
nation with nonselective venous sampling. An increase in
PTH levels after stimulation is compared with baseline. A
blush on the arteriogram is also considered a positive finding.
Powell et al. in a study from 2009 found that arteriography is
the best invasive procedure for localizing hyperfunctioning
parathyroid glands (92% PPV), before revision surgery [148].
Open issues
Primary hyperparathyroidism is usually caused by a solitary
parathyroid adenoma, which is relatively easy to detect.
However, in 15–20% of cases, it is caused by MGD, i.e.,
multiple adenomas or hyperplastic glands, which are more
difficult to diagnose with SPECT/CT and PET/CT techniques,
cUS, 4D-CT, andMRI. Additionally, in the last decades, there
is a trend toward minimally invasive parathyroidectomy
whenever possible, which may be another reason for missed
MGD. However, in suspected MGD, not identified by stan-
dard techniques, open neck exploration should remain as an
option. Another reason for failed imaging and unsuccessful
surgery is an ectopic parathyroid gland. The reasons for im-
aging failure in this setting may be an inadequate imaging
technique, failure to detect a rare ectopic site, as well as the
imprecisely reported location of the ectopic gland. An addi-
tional problem, not only related to MGD and ectopic sites, is
that not all hyperfunctioning parathyroid glands retain radio-
pharmaceuticals and the thyroid in certain cases does not show
adequate washout. In these circumstances, dynamic or sub-
traction imaging might be helpful.
Another potential problem is a failure to detect ectopic
glands in the pericardial region, due to the normal distribution
of cardiotropic SPECT radiopharmaceuticals in neighboring
myocardium. While these cases are extremely rare, they still
need to be recognized.
Additional problems are caused by discordant imaging re-
sults. Novel techniques, such as PET/MRI with 18F-labeled
choline analogues, appear to be promising in patients with
inconclusive results of standard imaging techniques [87].
PET/MRI might be even more advantageous than PET/CT,
owing to less radiation exposure and better soft-tissue contrast
in the neck, improving the morphological correlation of PET
findings. Current data exists from a few studies with up to 42
patients [87, 145, 146, 149], the majority of patients having
negative or equivocal standard imaging.
Another rare but important issue is the imaging of
parathyroid carcinoma and distinguishing it from benign
parathyroid lesions. Parathyroid carcinoma is typically
characterized by significant hypercalcemia and high
PTH levels, but there are no specific biochemical features
that allow for differentiation from benign parathyroid le-
sions. Several US features may be helpful in parathyroid
carcinoma cases, such as larger lesion size (> 3 cm), ir-
regular lesion borders with tissue invasion, heterogeneous
and decreased echogenicity, or tumor depth/with ratio of
≥1:1 [150]. Parathyroid carcinoma, its recurrences, and
minimally invasive parathyroid carcinoma, usually accu-
mulate [99mTc]Tc-MIBI [151–156], and recently it was
demonstrated that parathyroid carcinoma has a higher re-
tention level (mean and peak retention index) of
[99mTc]Tc-MIBI compared with benign lesions [157],
which may be helpful in the preoperative differential di-
agnosis. PET/CT with 18F-labeled choline analogues is
able to detect minimally invasive parathyroid carcinoma,
according to recently published papers [154]. It may also
detect local and distant recurrences of parathyroid carci-
noma by their high uptake [158, 159]. [18F]FDG PET/CT
may also provide information on loco-regional and dis-
tant spreading, presumably in less well-differentiated le-
sions [152, 160]. One isolated case of a [99mTc]Tc-MIBI-
negative and [18F]FDG-negative, but [11C]MET-positive
parathyroid carcinoma local recurrence has been de-
scribed [161]. Computed tomography and MRI are useful
for detecting the local extent of disease, invasion of sur-
rounding tissue, and distant spread. Fine-needle aspira-
tion is not recommended in suspected parathyroid carci-
noma, because cytology is not accurate in distinguishing
malignant from benign lesions, and it may cause seeding
of cancer cells [162].
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Another issue is discussed in a recent article regarding the
lack of specific criteria for the diagnosis of minimally invasive
parathyroid carcinoma [154]. It appears to be less aggressive
compared with “classic” parathyroid carcinoma and authors
suggest the importance of differentiating it from parathyroid
adenoma and parathyroid carcinoma.
Conclusions
The use of optimized first-line imaging for the detection and
precise localization of hyperfunctioning parathyroid glands is
important as the first operation is the best moment to obtain a
long-lasting cure. Combining [99mTc]Tc-MIBI SPECT/CT
with cUS performed by an experienced sonographer is a wide-
ly available and accepted first-line strategy. Different proto-
cols exist for [99mTc]Tc-MIBI scintigraphy. Dual-phase imag-
ing with SPECT/CT is a widely used technique. Dual-tracer
subtraction imaging is a valuable alternative option. PET/CT
with 18F-labeled choline analogues has shown superior re-
sults; however, data from large cohorts and on cost-
effectiveness are not currently available. It may be considered
a potential “alternative” first-line method whenever possible,
as it appears to be an effective technique even in patients with
negative/equivocal standard imaging findings. Other advan-
tages of this technique are the high resolution, the low radia-
tion exposure, and the shorter acquisition time. Modern sen-
sitive PET/CT scanners and the use of PET/MRI for 18F-la-
beled choline analogue imaging may result in significantly
less radiation exposure compared with [99mTc]Tc-MIBI
SPECT/CT. The drawbacks are higher costs compared with
[99mTc]Tc-MIBI, as well as local reimbursement and licensing
issues. There are several second-line techniques available after
negative or inconclusive first-line imaging. It is important to
obtain concordant imaging by two techniques whenever pos-
sible. [11C]MET is a radiopharmaceutical that may be used as
a second-line PET imaging tracer as it has an excellent detec-
tion performance. However, major drawbacks of this radio-
pharmaceutical are the short physical half-life of 11C which
demands an on-site cyclotron, the demanding labeling pro-
cess, poorer spatial resolution, local reimbursement, and li-
censing issues.
4D-CT may be useful in case of negative or inconclusive
other imaging studies, in patients with distorted neck anato-
my, or after futile surgery. It has similar diagnostic accuracy
compared with [99mTc]Tc-MIBI SPECT, but a higher radia-
tion exposure. 18F-labeled choline analogue PETmay be com-
bined with 4D-CT in complicated cases (e.g., re-operated pa-
tients) to enhance the sensitivity and PPV compared with ei-
ther technique alone. MRI may be also used after negative/
inconclusive first-line imaging or in pregnant patients.
Invasive diagnostic procedures remain as last resort.
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